Thursday, 20 August 2015 11:55

Public Alert On Falsified Diazepam

Rate this item
(0 votes)

The Agency has been notified of the confirmed circulation of falsified Diazepam tablets in Central Africa. This information was revealed on the 2nd of July, 2015 by the World Health Organization (WHO). Laboratory analysis report of a product labeled as Diazepam shows that it does not contain diazepam but contains between 10mg to 20mg of Haloperidol per tablet an anti-psychotic used for the treatment of schizophrenia. The tablets are light yellow, scored on one side and bear AGOG on the other side are contained in white plastic bottles of 1000 tablets. AGOG a pharmaceutical manufacturer have stated they do not manufacture Diazepam but manufacture Haloperidol with a similar description but supplied in blisters of 10 tablets and boxes of 10 blisters under the trade name of AGOHAL, Haloperidol tablet BP 10mg. The tablet marked with the trade name SOLINA, Diazepam tablet BP 5mg manufactured by CENTAUR Pharmaceuticals tested positive for Haloperidol.

According to CENTAUR Pharmaceutical, they do not manufacture Haloperidol but manufacture Diazepam. Report have also shown that over 400 patients in the north east region of the Democratic Republic of Congo (DRC) have suffered from an acute dystonic reaction affecting the muscles of the face, neck and tongue which is a known side effect of Haloperidol.

The falsified version of Diazepam labeled as manufactured by AGOG Pharma Ltd is being circulated in containers of 1000 tablets. AGOG Pharma has confirmed this labeling and packaging to be falsified and should not be used as they do not manufacture Diazepam.

Details of affected batches are:

Product 1

Product 2

Manufacturer: CENTUER Pharmaceuticals Ltd

Trade name: SOLINA

Product:   Diazepam BP 5mg

Batch Number: SBG038

Manufacturing date: September 2014

Expiry date: August 2017

Manufacturer: AGOG Pharma. Ltd

Trade name: DIAZEPAM TABLET

Product:   Diazepam BP 5mg

Batch Number: 2332

Manufacturing date: November 2013

Expiry date: October 2016

NAFDAC warns that health care providers and the general public should ensure vigilance and careful examination of product content bearing the above details. Also notify the Agency of any information concerning the supply of these products via e-mail:  This email address is being protected from spambots. You need JavaScript enabled to view it.

NAFDAC…..Safeguarding the health of the Nation

Read 10949 times Last modified on Monday, 06 June 2016 14:36

ONLINE PORTALS

napams

Contact Us from Mon - Friday: 08:00-16:00 GMT+1

Write Us:

NAFDAC Corporate Headquarters,

Plot 2032, Olusegun, Obasanjo Way,

Zone 7, Wuse, Abuja, Nigeria

 

Lagos Operation Office:

Plot 1, Industrial Estate, Lagos- Oshodi Apapa Express Way, Isolo, Lagos, Nigeria

 

 

 

 

 

 

For Enquiries:

Call: +234(0)-1-4609750

Email:nafdac@nafdac.gov.ng

 

 

 

 

 

 

 

 

 

 

 

For Complaints:

Call: +234(0)909-763-0506

         +234(0)909-763-0507

Email:reforms@nafdac.gov.ng

Or Send Us a Complaint

 

 

 

 

 

 

 

 

 

Contact Other NAFDAC Offices Nationwide